The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant

The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant

We previously demonstrated that soluble baculovirus-expressed African horsesickness virus (AHSV) serotype 5 VP2 protein (AHSV5 rVP2) elicits neutralising antibodies in guinea pigs. We have now determined the immunogenicity of soluble AHSV5 rVP2 in horses when administered in three different adjuvant...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine Vol. 20; no. 7; pp. 1079 - 1088
Main Authors: Scanlen, M, Paweska, J.T, Verschoor, J.A, van Dijk, A.A
Format: Journal Article
Language:English
Published: Netherlands Elsevier Ltd 15-01-2002
Subjects:
Adjuvant
Adjuvants, Immunologic - pharmacology
African Horse Sickness Virus - immunology
African horsesickness virus 5
AHSV5 rVP2
Aluminium phosphate
Animals
Capsid - immunology
Capsid Proteins
Horses
Hypersensitivity
Immunization
Reovirus
saponins
Saponins - adverse effects
Saponins - pharmacology
Vaccines, Subunit - immunology
Vaccines, Synthetic - immunology
Viral Vaccines - immunology
VP2 protein
AHSV5 rVP2
Hypersensitivity
Adjuvant
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We previously demonstrated that soluble baculovirus-expressed African horsesickness virus (AHSV) serotype 5 VP2 protein (AHSV5 rVP2) elicits neutralising antibodies in guinea pigs. We have now determined the immunogenicity of soluble AHSV5 rVP2 in horses when administered in three different adjuvant types, ISA-50, aluminium phosphate and different saponin preparations. Doses of 10 and 50 μg of rVP2 administered with saponin induced full protection to a lethal challenge, albeit with dose-related side effects. The results establish that soluble rVP2 is the biologically active form and that it can induce complete protection when it is delivered with saponin adjuvants. We conclude that the use of the soluble biologically active form of AHSV rVP2 and the choice of adjuvant will be crucial factors in determining efficacy, safety and the production cost of recombinant AHSV subunit vaccines.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(01)00445-5